The self-assembling peptide, our core technology, was discovered by Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) in the United States in 1992. The first-generation self-assembling peptide has been produced as PuraMatrix™.
Pipeline
Main Pipeline Development Status (June, 2024)
*You can scroll horizontally
Surgery
|
Product | Area | Non-clinical study |
Clinical study |
Application | Approval | Launch |
---|---|---|---|---|---|---|---|
Hemostat (Purastat) |
CE marking countries | ||||||
Japan | |||||||
US | |||||||
Prevention of delayed bleeding (Purastat) |
CE marking countries | ||||||
US | |||||||
Japan | |||||||
Next-generation hemostat (TDM-623) |
CE marking countries | ||||||
Anti-adhesion material (Purasinus) |
US | ||||||
Mucous membrane Lifting-up solution (TDM-644) |
Japan |
Tissue regeneration
|
Product | Area | Non-clinical study |
Clinical study |
Application | Approval | Launch |
---|---|---|---|---|---|---|---|
Wound healing Material (PuraDerm) |
US |
Preparing for cosmetic surgery
|
|||||
Rectal mucositis | US | ||||||
CE marking countries | |||||||
Japan | |||||||
Inflammatory bowel disease | CE marking countries | ||||||
Japan | |||||||
US |
DDS
|
Product | Area | Non-clinical study |
Clinical study |
Application | Approval | Launch |
---|---|---|---|---|---|---|---|
Triple negative breast cancer (TDM-812) |
Japan | ||||||
Malignant pleural mesothelioma (MIRX002) |
Japan |
Under development by licensee
|